Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Tumor Biology

Abstract #1162: Dual endothelin receptor antagonist treatment and inflammation in an immuno-competent model of breast cancer bone metastases

Claudia Castillo, Lauren Allen, Ashley Jewell, Heather Wyan, Jill Hudak and Didier Dréau
Claudia Castillo
Univ. of North Carolina, Charlotte, NC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lauren Allen
Univ. of North Carolina, Charlotte, NC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ashley Jewell
Univ. of North Carolina, Charlotte, NC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heather Wyan
Univ. of North Carolina, Charlotte, NC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jill Hudak
Univ. of North Carolina, Charlotte, NC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Didier Dréau
Univ. of North Carolina, Charlotte, NC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published May 2009
  • Article
  • Info & Metrics
Loading
AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

Abstract

We investigated the effects of endothelin-1 antagonists on the inflammation associated with breast cancer growth and the development of bone metastases. Murine mammary carcinoma 4T1 cells were injected in a skin-fold chamber implanted with bone explants on immuno-competent CB6 mice. Mice were treated with or without antagonists of ETRA, ETRB or both ET-1 receptors. The development of bone metastases was assessed by histological studies and the presence of cytokeratin-19 in bone explants. Inflammation was assessed by the presence of CD45+ and CD68+ cells in the tumor and bone. In addition, cytokine concentrations, present in tumor and bone samples, were assessed by ELISA. Results indicate that treatment with the ETBR antagonist was associated with significantly reduced tumor mass and tumor bone metastases. However, the observed inflammation was reduced by both treatment as measured by the number of macrophage / monocytes present (P<0.05). In addition, locally in both tumor and bone, ETRA antagonist treatments led to decreased expression of inflammatory cytokines (p<0.05). Furthermore, the changes in inflammation were correlated with smaller tumors and reduced bone invasion (p<0.05). Our data support the hypothesis that through ET-1 may promote the inflammation associated with the development of breast metastases to bone.

Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 1162.

Footnotes

  • 100th AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

  • American Association for Cancer Research
Back to top
Cancer Research: 69 (9 Supplement)
May 2009
Volume 69, Issue 9 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract #1162: Dual endothelin receptor antagonist treatment and inflammation in an immuno-competent model of breast cancer bone metastases
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract #1162: Dual endothelin receptor antagonist treatment and inflammation in an immuno-competent model of breast cancer bone metastases
Claudia Castillo, Lauren Allen, Ashley Jewell, Heather Wyan, Jill Hudak and Didier Dréau
Cancer Res May 1 2009 (69) (9 Supplement) 1162;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract #1162: Dual endothelin receptor antagonist treatment and inflammation in an immuno-competent model of breast cancer bone metastases
Claudia Castillo, Lauren Allen, Ashley Jewell, Heather Wyan, Jill Hudak and Didier Dréau
Cancer Res May 1 2009 (69) (9 Supplement) 1162;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Tumor Biology

  • Abstract SY34-04: Do we need to know what pO2 hypoxia is
  • Abstract SY28-04: Rational incorporation of novel agents into multimodality treatment of glioma and neuroblastoma
  • Abstract SY28-02: Connections in the BRCA1-BRCA2 pathway of homologous recombination: Implications for breast cancer development and treatment
Show more 3

Innate Immune Response in Tumorigenesis -- Poster Presentations - Proffered Abstracts

  • Abstract #1157: The metastasis suppressor RhoGDI2 modulates tumor-host interactions
  • Abstract #1153: Functional differences between induced T reg cells from tumor antigen specific CTL induction and influenza matrix antigen specific CTL induction cultures
  • Abstract #1154: IL-6 induces IL-10 expression and promotes cancer progression after activation of STAT3 in human colon carcinoma cells
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement